Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $3.79 billion. The enterprise value is $3.11 billion.
| Market Cap | 3.79B |
| Enterprise Value | 3.11B |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 193.97 million shares outstanding. The number of shares has increased by 1.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 193.97M |
| Shares Change (YoY) | +1.98% |
| Shares Change (QoQ) | +3.28% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 50.13% |
| Float | 90.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 28.35 |
| PS Ratio | 2.72 |
| Forward PS | 2.26 |
| PB Ratio | 3.11 |
| P/TBV Ratio | 2.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.21 |
| EV / EBITDA | 60.00 |
| EV / EBIT | 80.59 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.95, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.95 |
| Quick Ratio | 3.70 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 1.91 |
| Debt / FCF | n/a |
| Interest Coverage | 2.05 |
Financial Efficiency
Return on equity (ROE) is -0.02% and return on invested capital (ROIC) is -0.04%.
| Return on Equity (ROE) | -0.02% |
| Return on Assets (ROA) | 1.37% |
| Return on Invested Capital (ROIC) | -0.04% |
| Return on Capital Employed (ROCE) | 2.68% |
| Weighted Average Cost of Capital (WACC) | 6.96% |
| Revenue Per Employee | $411,667 |
| Profits Per Employee | -$61 |
| Employee Count | 3,300 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 16.94 |
Taxes
In the past 12 months, Legend Biotech has paid $32.40 million in taxes.
| Income Tax | 32.40M |
| Effective Tax Rate | 100.62% |
Stock Price Statistics
The stock price has decreased by -38.14% in the last 52 weeks. The beta is 0.55, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -38.14% |
| 50-Day Moving Average | 19.72 |
| 200-Day Moving Average | 22.19 |
| Relative Strength Index (RSI) | 44.58 |
| Average Volume (20 Days) | 2,324,711 |
Short Selling Information
The latest short interest is 13.90 million, so 16.91% of the outstanding shares have been sold short.
| Short Interest | 13.90M |
| Short Previous Month | 16.39M |
| Short % of Shares Out | 16.91% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.10 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $1.36 billion and -$200,000 in losses. Loss per share was -$0.01.
| Revenue | 1.36B |
| Gross Profit | 774.10M |
| Operating Income | 37.30M |
| Pretax Income | 32.20M |
| Net Income | -200,000 |
| EBITDA | 50.10M |
| EBIT | 37.30M |
| Loss Per Share | -$0.01 |
Balance Sheet
The company has $852.50 million in cash and $167.40 million in debt, with a net cash position of $685.10 million or $3.53 per share.
| Cash & Cash Equivalents | 852.50M |
| Total Debt | 167.40M |
| Net Cash | 685.10M |
| Net Cash Per Share | $3.53 |
| Equity (Book Value) | 1.27B |
| Book Value Per Share | 6.56 |
| Working Capital | 855.20M |
Cash Flow
In the last 12 months, operating cash flow was -$154.10 million and capital expenditures -$28.60 million, giving a free cash flow of -$182.70 million.
| Operating Cash Flow | -154.10M |
| Capital Expenditures | -28.60M |
| Depreciation & Amortization | 30.70M |
| Net Borrowing | -3.60M |
| Free Cash Flow | -182.70M |
| FCF Per Share | -$0.94 |
Margins
Gross margin is 56.98%, with operating and profit margins of 2.75% and -0.01%.
| Gross Margin | 56.98% |
| Operating Margin | 2.75% |
| Pretax Margin | 2.37% |
| Profit Margin | -0.01% |
| EBITDA Margin | 3.69% |
| EBIT Margin | 2.75% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.98% |
| Shareholder Yield | -1.98% |
| Earnings Yield | -0.06% |
| FCF Yield | -4.95% |
Analyst Forecast
The average price target for Legend Biotech is $42.69, which is 118.48% higher than the current price. The consensus rating is "Buy".
| Price Target | $42.69 |
| Price Target Difference | 118.48% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 23.67% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 6.49 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.49 |
| Piotroski F-Score | 3 |